{
  "id": 19917870,
  "title": "Jubilant Pharmova's Q2 Earnings Take A Bitter Pill, Net Profit Crashes 74% To ₹31 Crore Despite Generics Growth",
  "url": "https://urgent.news/2026/11/14/jubilant-pharmovas-q2-earnings-take-a-bitter-pill-net-profit-crashes",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-14T04:10:52.000Z",
  "source": {
    "name": "Free Press Journal",
    "slug": "free-press-journal",
    "url": "https://www.freepressjournal.in/business/jubilant-pharmovas-q2-earnings-take-a-bitter-pill-net-profit-crashes-74-to-31-crore-despite-generics-growth"
  },
  "original_language": "en",
  "account": "Mumbai, September 30, 2026 - Jubilant Pharmova Limited, a leading pharmaceutical company, disclosed a significant drop in net profit during the second quarter of fiscal year 2027, despite a surge in revenue from its generics and sterile injectables businesses. Total income for the quarter amounted to ₹2,384 crore, with the company's net profit shrinking by approximately 74% to ₹31 crore, a dramatic decline from ₹120 crore during the same quarter last year. Earnings before interest, tax, depreciation, and amortisation (EBITDA) also fell 27% year-on-year to ₹255 crore, indicating challenges in maintaining operating profitability. The generics segment exhibited robust growth, rising by 64% to ₹274 crore, while the CDMO sterile injectables business grew 33% to ₹522 crore. However, the Radiopharma business showed weaker performance, recording ₹1,009 crore in revenue. In a strategic move, Jubilant Pharmova successfully raised ₹800 crore through non-convertible debentures (NCDs) to be used for debt refinancing and capital expenditure requirements.",
  "summary": "Mumbai: Jubilant Pharmova Limited reported a sharp decline in profitability during the second quarter of FY27, with its net profit falling approximately 74% year-on-year to ₹31 crore, despite strong revenue growth in its generics and sterile injectables businesses. The pharmaceutical company reported total income of ₹2,384 crore for the quarter ended September 30, 2026. Jubilant Ingrevia Records…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}